Literature DB >> 32064088

Physicochemical stability of etoposide diluted at range concentrations between 0.38 and 1.75 mg/mL in polyolefin bags.

Elise D'Huart1, Jean Vigneron1, Pauline Lider1, Béatrice Demoré1,2.   

Abstract

Introduction: According to the manufacturers, the diluted solution of etoposide should not exceed 0.4 mg/mL because precipitation may occur. For high doses or for patients requiring fluid restrictions, etoposide phosphate may be an option but shortages occurs frequently. The objective of this work was to study the stability of etoposide solutions between 0.38 and 1.75 mg/mL, diluted in 0.9% sodium chloride (0.9% NaCl) or 5% glucose (G5%) in polyolefin bags, stored at 25°C and between 2°C to 8°C, in a 61-day period. This study also observed the impact of an infusion pump on the physical and chemical stability of etoposide solutions. Materials and method: Chemical stability was analysed at days 0, 9, 16, 21, 28 and 61 by high-performance liquid chromatography. Physical stability was evaluated by visual and subvisual inspection. The action of an infusion pump on solutions was evaluated to verify the impact of the mechanical pumping action on the etoposide solutions. This investigation was performed at day 61, at the end of the study.
Results: Etoposide solutions diluted at 0.38, 0.74 and 1.26 mg/mL in G5% and stored at 25°C were stable for 61 days and at 1.75 mg/mL for 28 days. In 0.9% NaCl, etoposide was less stable, with more precipitations observed. The action of an infusion pump has not caused any physical modifications.
Conclusion: Storage at 25°C and G5% as diluent are recommended for etoposide high concentration with 61-day stability up to a concentration of 1.26 mg/mL and 28-day stability up to a concentration of 1.75 mg/mL. As a precaution, the use of an administration set with an in-line micro-filter is nevertheless recommended. Storage at 2°C to 8°C and the use of 0.9% NaCl increase the risk of precipitation. © European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  HPLC; chemotherapy; drug stability; etoposide; storage conditions

Year:  2018        PMID: 32064088      PMCID: PMC6992966          DOI: 10.1136/ejhpharm-2018-001571

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  6 in total

1.  Guidelines for the practical stability studies of anticancer drugs: a European consensus conference.

Authors:  C Bardin; A Astier; A Vulto; G Sewell; J Vigneron; R Trittler; M Daouphars; M Paul; M Trojniak; F Pinguet
Journal:  Ann Pharm Fr       Date:  2011-08-03

2.  Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids.

Authors:  J H Beijnen; A U Beijnen-Bandhoe; A C Dubbelman; R van Gijn; W J Underberg
Journal:  J Parenter Sci Technol       Date:  1991 Mar-Apr

3.  Comparison of visual and turbidimetric methods for determining short-term compatibility of intravenous critical-care drugs.

Authors:  J F Dasta; K N Hale; G L Stauffer; M M Tschampel
Journal:  Am J Hosp Pharm       Date:  1988-11

4.  Stability and compatibility of etoposide in 0.9% sodium chloride injection in three containers.

Authors:  D M Barthes; E B Rochard; I J Pouliquen; S M Rabouan; P Y Courtois
Journal:  Am J Hosp Pharm       Date:  1994-11-01

5.  Precipitation of paclitaxel during infusion by pump.

Authors:  R W Pfeifer; K N Hale; S E Cronquist; M Daniels
Journal:  Am J Hosp Pharm       Date:  1993-12

6.  Stability of the i.v. and oral formulations of etoposide in solution.

Authors:  S P Joel; P I Clark; M L Slevin
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  6 in total
  1 in total

1.  High concentrated etoposide solutions, additional physical stability data in dextrose 5.

Authors:  Marine Ravey; Caroline Polo; Elise D'Huart; Jean Vigneron; Béatrice Demoré
Journal:  Eur J Hosp Pharm       Date:  2020-10-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.